Diplomat added to limited-distribution network for Cornerstone Therapeutics’ Bethkis
FLINT, Mich. — Cornerstone Therapeutics has added specialty pharmacy Diplomat to its limited-distribution network for a newly approved treatment for cystic fibrosis, Diplomat said Friday.
Diplomat will distribute Bethkis (tobramycin inhalation solution), which received Food and Drug Administration approval in October for treating chronic bacterial lung infections caused by P. aeruginosa in cystic fibrosis patients.
Cystic fibrosis affects more than 30,000 children and adults, according to the Cystic Fibrosis Foundation, with 1,000 new cases diagnosed each year.
Correction: The original statement from Diplomat incorrectly referred to the name of Cornerstone Therapeutics. This version of the story corrects the original.
Sandoz launches authorized generic version of PharmaDerm’s Solaraze
PRINCETON, N.J. — Sandoz has launched an authorized generic version of a topical drug for treating actinic keratosis, the company said.
Sandoz, the generics arm of Swiss drug maker Novartis, announced the launch of authorized generic diclofenac gel in the 3% strength. The drug is a version of PharmaDerm’s Solaraze.
The drug had sales of $92 million in 2012, according to IMS Health. Authorized generics are branded drugs marketed under their generic names at a discounted price, usually under a contract between the branded drug’s manufacturer and a third-party company.
Actinic keratosis, or AK, is a precancerous condition affecting 58 million Americans that causes thick, scaly or crusty patches of skin.
Teva launches generic drug for cystic fibrosis patients
JERUSALEM — Teva Pharmaceutical Industries has launched its generic version of a drug for patients with cystic fibrosis, the Israeli drug maker said Thursday.
Teva announced the launch of tobramycin inhalation solution, a generic version of Novartis’ drug Tobi. The Food and Drug Administration approved Teva’s product last month. The drug is used to treat CF in patients whose lungs contain bacteria called Pseudomonas aeroginosa.
Tobi had sales of about $350 million during the 12-month period that ended in June, according to IMS Health.